TLDR Combining dutasteride or finasteride with an α1 blocker is more effective for managing BPH than using either alone.
The study reviewed the management of benign prostatic hyperplasia (BPH) using combination therapy involving 5α Reductase inhibitors (such as dutasteride or finasteride) and α1 adrenoreceptor blockers. It aimed to determine if this combination therapy was more effective than monotherapy. The research focused on the safety, efficacy, and development of these treatment agents. The study concluded that combination therapy could potentially offer superior benefits in managing BPH compared to using either treatment alone.
52 citations
,
February 2006 in “Current pharmaceutical design” 5α-reductase inhibitors and alpha-1 adrenergic antagonists together effectively treat benign prostatic hyperplasia, with long-term benefits.
2 citations
,
January 2023 in “Uro” UHP-sCESr is as effective as HESr for treating BPH symptoms.
14 citations
,
November 2006 in “Current Medicinal Chemistry” New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.
35 citations
,
May 2020 in “Frontiers in Pharmacology” Different drugs for prostate-related urinary symptoms work but have various side effects, and treatment should be tailored to the individual.
20 citations
,
August 2019 in “Expert Opinion on Drug Safety” Some medications for bladder problems can cause memory issues or mood changes, and doctors should monitor these side effects.